Scarica l'app Stockscreener
2.84
1.79%
0.05
Sab Biotherapeutics Inc Borsa (SABS) Ultime notizie
What analysts say about SAB Biotherapeutics Inc. Equity Warrant stockFree Investment Community - Jammu Links News
SAB Biotherapeutics Holds Annual Stockholders Meeting - TipRanks
Why SAB Biotherapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
Why DUOL stock attracts strong analyst attentionHigh Return Setup Scanner - Newser
What makes SAB Biotherapeutics Inc. stock price move sharplyBreakout Confirmation Tool - Newser
How SAB Biotherapeutics Inc. stock performs during market volatilityLow Risk Trading Ideas - Newser
Why SAB Biotherapeutics Inc. Equity Warrant stock attracts strong analyst attentionFree Predictions - Newser
How SAB Biotherapeutics Inc. Equity Warrant stock performs during market volatility10x Potential Stocks - Newser
What makes SAB Biotherapeutics Inc. Equity Warrant stock price move sharplyFree Predictions - Newser
Millennium Management LLC Decreases Stock Holdings in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
Northern Trust Corp Invests $43,000 in SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital - Defense World
Analysts Offer Predictions for SABS Q2 Earnings - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Monday - Defense World
HC Wainwright Initiates Coverage on SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Brookline Capital Management Comments on SABS Q2 Earnings - Defense World
SABS Maintains Buy Rating by Chardan Capital with $20 Target | S - GuruFocus
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
SAB Biotherapeutics (SABS) Receives New "Buy" Rating from Analys - GuruFocus
SAB Biotherapeutics (SABS) Receives Buy Rating and $10 Target fr - GuruFocus
Head to Head Analysis: SAB Biotherapeutics (SABS) and Its Peers - Defense World
SAB BIO (SABS) Reports Cash Decrease as Progress in T1D Therapy Advances | SABS Stock News - GuruFocus
SAB Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates - GlobeNewswire
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Shares Purchased by Geode Capital Management LLC - Defense World
Financial Review: SAB Biotherapeutics (SABS) & The Competition - Defense World
Head-To-Head Review: SAB Biotherapeutics (SABS) versus Its Peers - Defense World
SAB Biotherapeutics (SABS) & Its Peers Head to Head Contrast - Defense World
SAB Biotherapeutics Reports 2024 Financial Results and Advances T1D Therapy - TipRanks
Influenza Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
FY2025 Earnings Forecast for SABS Issued By Chardan Capital - Defense World
HC Wainwright Brokers Boost Earnings Estimates for SABS - Defense World
SAB Biotherapeutics’ (SABS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $20.00 by Analysts at Chardan Capital - Defense World
HC Wainwright Reaffirms “Buy” Rating for SAB Biotherapeutics (NASDAQ:SABS) - The AM Reporter
Craig-Hallum Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
SAB Biotherapeutics price target lowered to $20 from $25 at Chardan - TipRanks
Promising Outlook for SAB Biotherapeutics’ SAB-142: Positive Phase 1 Results and Future Growth Potential Justify Buy Rating - TipRanks
SAB BIO Reports Full Year 2024 Operating and Financial Results - GlobeNewswire
SAB Bio's Diabetes Breakthrough: Phase 1 Success Drives Path to Phase 2b Trials - Stock Titan
SAB Biotherapeutics held cash and equivalents of $20.8 million at end of 2024 - TipRanks
SAB Biotherapeutics, Inc. SEC 10-K Report - TradingView
Financial Contrast: SAB Biotherapeutics (NASDAQ:SABS) versus Kiromic BioPharma (NASDAQ:KRBP) - Defense World
SAB Biotherapeutics (SABS) to Release Earnings on Thursday - Defense World
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):